Wu et al. found that the aldose reductase inhibitor fidarestat can reduce the expression of AKR1B10 in NK cells, thereby promoting NK cell glycolysis and enhancing its killing activity against liver cancer cells41. This evidence concerns the gene AKR1B10 and liver cancer.